Welwaze Medical develops Celbrea®, a breast thermal activity indicator that detects elevated temperature as a thermal biomarker for early breast disease detection. This device enhances traditional examination methods, providing physicians with an additional tool to improve breast health management for women.
Funding
$37M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Existing methods for early breast disease detection, such as physical exams and mammography, may not always detect subtle changes in breast tissue, potentially leading to delayed diagnosis. These methods may also expose patients to radiation or require specialized equipment and trained personnel, limiting accessibility and increasing costs.
Solution
Welwaze Medical's Celbrea® is a breast thermal activity indicator designed to detect elevated temperature as a thermal biomarker that may indicate early breast disease. The device is intended to be used by physicians as an adjunct to routine physical examinations, mammography, and other established procedures. Celbrea® aims to provide an additional data point for physicians to improve breast health management for women. By detecting thermal activity, Celbrea® offers a non-invasive method that complements existing screening techniques.
Target Audience
The primary target audience includes physicians and healthcare providers specializing in women's health and breast cancer screening, as well as women seeking proactive breast health management solutions.
Features
- Detects elevated temperature as a thermal biomarker.
- Designed for use as an adjunct to routine physical exams and mammography.
- Provides additional information for physicians in breast health management.
- Non-invasive method for detecting potential early breast disease indicators.